

Francesco Costa

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3878593/francesco-costa-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62

papers

4,886

citations

22

h-index

69

g-index

87

ext. papers

6,187

ext. citations

5.1

avg. IF

4.84

L-index

#	Paper	IF	Citations
62	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2018 , 39, 213-260	9.5	1475
61	Long-term use of ticagrelor in patients with prior myocardial infarction. <i>New England Journal of Medicine</i> , 2015 , 372, 1791-800	59.2	1193
60	Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. <i>Lancet, The</i> , 2017 , 389, 1025-1034	40	543
59	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. <i>European Heart Journal</i> , 2016 , 37, 390-9	9.5	232
58	Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2015 , 350, h1618	5.9	218
57	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2018 , 53, 34-78	3	149
56	Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 741-754	15.1	123
55	Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. <i>European Heart Journal</i> , 2017 , 38, 804-810	9.5	114
54	Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 426-36	5	99
53	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIX. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2592-2592	15.1	95
52	Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) study. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1412-21	9.5	61
51	Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	49
50	The Rotterdam Radial Access Research: Ultrasound-Based Radial Artery Evaluation for Diagnostic and Therapeutic Coronary Procedures. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9, e003129	6	41
49	Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. <i>EuroIntervention</i> , 2015 , 11, 68-74	3.1	40
48	Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study trial. <i>American Heart Journal</i> , 2016 , 174, 95-102	4.9	37
47	Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). <i>European Heart Journal</i> , 2019 , 40, 2070-2085	9.5	35
46	Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration. <i>EuroIntervention</i> , 2016 , 11, e1222-30	3.1	27

45	Impact of vascular access on acute kidney injury after percutaneous coronary intervention. <i>Cardiovascular Revascularization Medicine</i> , 2016 , 17, 333-8	1.6	26
44	Impact of greater than 12-month dual antiplatelet therapy duration on mortality: Drug-specific or a class-effect? A meta-analysis. <i>International Journal of Cardiology</i> , 2015 , 201, 179-81	3.2	23
43	Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the all-comer PRODIGY trial. <i>Catheterization and Cardiovascular Interventions</i> , 2015 , 87, F10-27	2.7	23
42	Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial. <i>International Journal of Cardiology</i> , 2015 , 187, 110-117	3.2	22
41	Benefit of radial approach in reducing the incidence of acute kidney injury after percutaneous coronary intervention: a meta-analysis of 22,108 patients. <i>International Journal of Cardiology</i> , 2015 , 179, 309-11	3.2	21
40	Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. <i>European Heart Journal</i> , 2018 , 39, e1-e33	9.5	18
39	Double or triple antithrombotic therapy after coronary stenting and atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials. <i>International Journal of Cardiology</i> , 2020 , 302, 95-102	3.2	15
38	Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies. <i>Drugs</i> , 2017 , 77, 1733-1754	12.1	13
37	Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization : Fifty Years of Revascularization: Where Are We and Where Are We Heading?. <i>Journal of Cardiovascular Translational Research</i> , 2015 , 8, 211-20	3.3	13
36	The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short. <i>Cardiovascular Diagnosis and Therapy</i> , 2018 , 8, 630-646	2.6	13
35	Radial Artery Access for Percutaneous Cardiovascular Interventions: Contemporary Insights and Novel Approaches. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	8
34	Coronary stent selection and optimal course of dual antiplatelet therapy in patients at high bleeding or thrombotic risk: navigating between limited evidence and clinical concerns. <i>Current Opinion in Cardiology</i> , 2015 , 30, 325-32	2.1	8
33	A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making. <i>American Heart Journal</i> , 2020 , 223, 44-47	4.9	8
32	Anatomic characteristics and clinical implications of angiographic coronary thrombus: insights from a patient-level pooled analysis of SYNTAX, RESOLUTE, and LEADERS Trials. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8,	6	6
31	Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let's Re-Evaluate Our Priorities. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1203-4	15.1	6
30	Bleeding risk stratification in acute coronary syndromes. Is it still valid in the era of the radial approach?. <i>Postępy W Kardiologii Interwencyjnej</i> , 2015 , 11, 170-3	0.4	6
29	Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions. <i>EuroIntervention</i> , 2021 , 17, 59-66	3.1	6
28	A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 1298-1307	3.8	5

27	Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial. <i>International Journal of Cardiology</i> , 2015 , 190, 242-5	3.2	4
26	Does Large Vessel Size Justify Use of Bare-Metal Stents in Primary Percutaneous Coronary Intervention?. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e007705	6	3
25	Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the PRISM Trial. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1667-76	5	3
24	Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	3
23	Fibrosis after Myocardial Infarction: An Overview on Cellular Processes, Molecular Pathways, Clinical Evaluation and Prognostic Value. <i>Medical Sciences (Basel, Switzerland)</i> , 2021 , 9,	3.3	3
22	Obstructive sleep apnoea syndrome and endothelial function: potential impact of different treatment strategies-meta-analysis of prospective studies. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019 , 276, 2331-2338	3.5	2
21	Actualizaci3n ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria, desarrollada en colaboraci3n con la EACTS. <i>Revista Espanola De Cardiologia</i> , 2018 , 71, 42.e1-42.e58	1.5	2
20	Tratamiento antitromb3tico en s3ndrome coronario agudo: buscando el equilibrio. <i>Revista Espanola De Cardiologia</i> , 2018 , 71, 782-786	1.5	2
19	Transesophageal Contrast Echocardiography is Not Always the Gold Standard Method in the Identification of a Patent Foramen Ovale: A Clinical Case. <i>Journal of Cardiovascular Echography</i> , 2015 , 25, 86-89	0.6	2
18	Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e006582	5.8	2
17	Antithrombotic Therapy for Percutaneous Cardiovascular Interventions: From Coronary Artery Disease to Structural Heart Interventions. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	2
16	Complexity of Antiplatelet Therapy in Coronary Artery Disease Patients. <i>American Journal of Cardiovascular Drugs</i> , 2021 , 21, 21-34	4	2
15	Accuracy of the PARIS score and PCI complexity to predict ischemic events in patients treated with very thin stents in unprotected left main or coronary bifurcations. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 97, E227-E236	2.7	2
14	Everolimus-eluting bioresorbable vascular scaffolds implanted in coronary bifurcation lesions: Impact of polymeric wide struts on side-branch impairment. <i>International Journal of Cardiology</i> , 2016 , 221, 656-64	3.2	1
13	Impellent impeller-Switching intra-aortic balloon pump to IMPELLA-CP after ST-segment elevation myocardial infarction and refractory cardiogenic shock. <i>Clinical Case Reports (discontinued)</i> , 2019 , 7, 1469-1472	0.7	1
12	Reply: Use of Clinical Risk Score in an Elderly Population: Need for Ad Hoc Validation and Calibration. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 162-163	15.1	1
11	Antithrombotic strategies in patients needing oral anticoagulation undergoing percutaneous coronary intervention: A network meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 97, 581-588	2.7	1
10	DAPT Score to Stratify Ischemic and Bleeding Risk after Percutaneous Coronary Intervention: An Updated Systematic Review, Meta-Analysis, and Meta-Regression of 100,211 Patients. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 687-689	7	1

9	Role of Adenosine and Purinergic Receptors in Myocardial Infarction: Focus on Different Signal Transduction Pathways. <i>Biomedicines</i> , 2021 , 9,	4.8	1
8	The Incidence and Impact of In-Hospital Bleeding in Patients with Acute Coronary Syndrome during the COVID-19 Pandemic. <i>Journal of Clinical Medicine</i> , 2022 , 11, 2926	5.1	1
7	Myocardial ischemia due to a recanalized chronic coronary thrombus: Angiographic and optical coherence tomography imaging insights. <i>Clinical Case Reports (discontinued)</i> , 2020 , 8, 1582-1583	0.7	
6	Response by Costa et al to Letter Regarding Article, "The Rotterdam Radial Access Research: Ultrasound-Based Radial Artery Evaluation for Diagnostic and Therapeutic Coronary Procedures". <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9,	6	
5	A Look Beyond Statins and Ezetimibe: a Review of Other Lipid-Lowering Treatments for Cardiovascular Disease Prevention in High-Risk Patients. <i>Current Cardiovascular Risk Reports</i> , 2019 , 13, 1	0.9	
4	Radial and Femoral Access in Percutaneous Intervention 2015 , 361-371		
3	Coronary aneurysm formation following bare-metal stent implantation: an optical coherence tomography evaluation. <i>Minerva Cardiology and Angiology</i> , 2017 , 65, 196-198	2.4	
2	The High Bleeding Risk Patient with Coronary Artery Disease. <i>Cardiology Clinics</i> , 2020 , 38, 481-490	2.5	
1	Competing risks in the duration of dual antiplatelet therapy: the case for shorter treatment 2021 , 111-130		